Brain Cancer patients in the Mid-South now have a promising new treatment method at West Cancer Center. Optune™, a portable device using low intensity electric fields to inhibit cancer cell replication causing death of cancer cells, is the first FDA-approved therapy in more than a decade to show a significant extension in overall survival rates for newly diagnosed adult Glioblastoma Multiforme (GBM) patients. Currently, West Cancer Center is the only medical center in Tennessee and the Mid-South to offer both the prescribing and planning of Optune™ as standard of care for GBM.

“Optune™ is reflective of West Cancer Center’s multidisciplinary approach and is indicative of our commitment to build a world-class Comprehensive Neuro-Oncology Program,” said Dr. Ballo. “We truly believe in the basic science behind this and are seeking opportunities for expanding its use through Phase I through III clinical trials and neurocognitive studies.”

To read more, please visit